Mylan Announces Approvals.Business &Medical Editors PITTSBURGH--(BUSINESS WIRE)--Feb. 17, 2000 Mylan Laboratories Inc. (NYSE NYSE See: New York Stock Exchange :MYL) announced today that it has received final approval to manufacture and market Terazosin Hydrochloride Capsules in 1mg, 2mg, 5mg, and 10mg strengths. Terazosin is the generic equivalent to Hytrin(R), an alpha-1-selective adrenoceptor blocking agent manufactured and marketed by Abbott Laboratories Inc. The product is indicated for the treatment of symptomatic Benign Prostatic Hyperplasia benign prostatic hyperplasia n. Abbr. BPH A nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50, and sometimes leading to compression of the urethra and obstruction of the flow of urine. (BPH BPH abbr. benign prostatic hyperplasia BPH Benign prostatic hypertrophy, a very common noncancerous cause of prostatic enlargement in older men. ). It is also indicated for the treatment of hypertension. The product is being manufactured in Mylan's Morgantown, West Virginia facility. Shipment is beginning immediately. Mylan has also been shipping Hydrochlorothiazide hydrochlorothiazide /hy·dro·chlo·ro·thi·a·zide/ (-klor?o-thi´ah-zid) a thiazide diuretic, used for treatment of hypertension and edema. hy·dro·chlo·ro·thi·a·zide n. Abbr. Capsules, 12.5mg, a first approval the company received at the end of January. The product is the generic equivalent to Watson's Microzide(R), an antihypertensive. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion